{"id":"placebo-cisplatin-carboplatin-paclitaxel-bevacizumab","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"20-40","effect":"Neuropathy (peripheral)"},{"rate":"30-50","effect":"Nausea/vomiting"},{"rate":"20-30","effect":"Hypertension"},{"rate":"10-20","effect":"Proteinuria"},{"rate":"5-15","effect":"Bleeding/hemorrhage"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cisplatin or carboplatin cross-link DNA to induce cancer cell death, while paclitaxel stabilizes microtubules to disrupt cell division. Bevacizumab is a VEGF inhibitor that prevents new blood vessel formation, starving tumors of nutrients and oxygen. Together, these agents provide complementary cytotoxic and anti-angiogenic effects against solid tumors.","oneSentence":"This combination regimen uses platinum-based chemotherapy and a taxane to damage cancer cell DNA, combined with an anti-angiogenic monoclonal antibody to block tumor blood vessel formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:24.429Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (specific indication dependent on phase 3 trial design)"}]},"trialDetails":[{"nctId":"NCT03635567","phase":"PHASE3","title":"Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-25","conditions":"Cervical Cancer","enrollment":617},{"nctId":"NCT04982237","phase":"PHASE3","title":"A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2021-08-27","conditions":"Cervical Cancer","enrollment":445},{"nctId":"NCT06459687","phase":"PHASE3","title":"Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"Lee's Pharmaceutical Limited","startDate":"2024-11-28","conditions":"Cervical Cancer","enrollment":440},{"nctId":"NCT05179239","phase":"PHASE3","title":"A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer","status":"TERMINATED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-02-26","conditions":"Cervical Cancer","enrollment":31},{"nctId":"NCT06755515","phase":"PHASE2, PHASE3","title":"A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2024-09-26","conditions":"Cervical Cancer","enrollment":510},{"nctId":"NCT05798819","phase":"PHASE3","title":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2023-05-01","conditions":"Persistent, Recurrent, or Metastatic Cervical Cancer","enrollment":424},{"nctId":"NCT05715840","phase":"PHASE3","title":"Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-01-31","conditions":"Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)","enrollment":368},{"nctId":"NCT05446883","phase":"PHASE3","title":"QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2022-09-23","conditions":"METASTATIC CERVICAL CANCER","enrollment":498},{"nctId":"NCT03912415","phase":"PHASE3","title":"Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)","status":"UNKNOWN","sponsor":"Biocad","startDate":"2019-10-01","conditions":"Cervical Cancer","enrollment":316},{"nctId":"NCT01383148","phase":"PHASE2, PHASE3","title":"Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Transgene","startDate":"2012-04","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":222},{"nctId":"NCT01496742","phase":"PHASE2","title":"A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-04","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":259}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab","genericName":"Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab","companyName":"Lee's Pharmaceutical Limited","companyId":"lee-s-pharmaceutical-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses platinum-based chemotherapy and a taxane to damage cancer cell DNA, combined with an anti-angiogenic monoclonal antibody to block tumor blood vessel formation. Used for Advanced or metastatic solid tumors (specific indication dependent on phase 3 trial design).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}